BlackRock Inc. has acquired a new position in Neumora Therapeutics, Inc., purchasing 7,791,869 shares, according to a recent Form 13F filing with the Securities & Exchange Commission. The investment is valued at approximately $13.25 million and gives BlackRock a 4.21% stake in the company.
This disclosure of a significant new institutional investor comes as Neumora's stock has been trading well below its 50-day and 200-day moving averages. The addition of a prominent investor like BlackRock could be seen as a positive signal by the market regarding the company's future prospects. Institutional investors now collectively own 47.65% of Neumora's stock.